NCT06105554: Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma |
|
|
| Recruiting | 1/2 | 36 | US | Belumosudil mesylate | M.D. Anderson Cancer Center, Sanofi US Services, Inc | Multiple Myeloma | 08/27 | 08/29 | | |
NCT01301807: Panobinostat and Carfilzomib in Treating Participants With Relapsed or Refractory Multiple Myeloma |
|
|
| Completed | 1 | 63 | US | Carfilzomib, Kyprolis, PR-171, Panobinostat, Faridak, Farydak, LBH589 | M.D. Anderson Cancer Center, National Cancer Institute (NCI) | Non-Secretory Plasma Cell Myeloma, Plasmacytosis, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | 11/19 | 11/19 | | |
NCT05698303: A Study of Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (CT103A) in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma |
|
|
| Not yet recruiting | 1 | 12 | US | Fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A), CT103A | Nanjing IASO Biotherapeutics Co.,Ltd | Multiple Myeloma | 05/24 | 01/26 | | |
